• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

Decernotinib

Product ID D364086
Cas No. 944842-54-0
Purity ≥99%
Product Unit SizeCostQuantityStock
1 mg $80.40 In stock
5 mg $166.90 In stock
25 mg $475.90 In stock
100 mg $958.00 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Decernotinib is a potent and selective inhibitor of JAK3. It exhibits anti-inflammatory effects in rat models of rheumatoid arthritis, while avoiding hematopoiesis, a problem with current non-selective JAK inhibitors. Methotrexate treatment is also improved when used in combination with decernotinib.

Product Info

Cas No.

944842-54-0

Purity

≥99%

Formula

C18H19F3N6O

Formula Wt.

392.39

IUPAC Name

N2-[2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]-N-(2,2,2-trifluoroethyl)-D-isovalinamide

Synonym

VX-509, VRT-831509, Adelitinib

Solubility

DMSO

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

D364086 MSDS PDF

Info Sheet

D364086 Info Sheet PDF

References

Farmer L., Ledeboer M., et al. Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases. J Med Chem. 58(18):7195-216 (2015). PMID: 26230873.

Elwood F., Witter D., et al. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor. 361(2):229-44 (2017). PMID:28193636.

Genovese M., van Vollenhoven R., et al. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 68(1):46-55 (2016). PMID: 26473751.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only